M&G Plc Makes New Investment in Axon Enterprise, Inc. (NASDAQ:AXON)

M&G Plc bought a new position in Axon Enterprise, Inc. (NASDAQ:AXON) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 39,334 shares of the biotechnology company’s stock, valued at approximately $12,312,000. M&G Plc owned 0.05% of Axon Enterprise at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Axon Enterprise in the fourth quarter valued at $195,406,000. Motley Fool Asset Management LLC increased its holdings in shares of Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after buying an additional 346,838 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of Axon Enterprise in the fourth quarter valued at $39,907,000. Goldman Sachs Group Inc. increased its holdings in shares of Axon Enterprise by 110.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company’s stock valued at $71,302,000 after buying an additional 144,568 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of Axon Enterprise in the fourth quarter valued at $14,273,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on AXON. Bank of America began coverage on Axon Enterprise in a report on Wednesday. They issued a “buy” rating and a $380.00 price target on the stock. Barclays boosted their target price on shares of Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a research note on Wednesday, May 8th. Needham & Company LLC reissued a “buy” rating and set a $400.00 target price on shares of Axon Enterprise in a research note on Tuesday, May 7th. Craig Hallum boosted their target price on shares of Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Finally, Jefferies Financial Group started coverage on shares of Axon Enterprise in a research note on Wednesday. They set a “buy” rating and a $385.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $342.54.

Axon Enterprise Stock Up 0.9 %

NASDAQ:AXON traded up $2.78 during trading hours on Friday, reaching $308.45. The company’s stock had a trading volume of 269,770 shares, compared to its average volume of 477,359. The company has a market cap of $23.28 billion, a price-to-earnings ratio of 90.19, a price-to-earnings-growth ratio of 6.95 and a beta of 0.95. Axon Enterprise, Inc. has a one year low of $175.37 and a one year high of $329.87. The business’s 50-day moving average is $292.47 and its 200-day moving average is $289.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The company had revenue of $460.74 million during the quarter, compared to analysts’ expectations of $441.57 million. During the same period in the prior year, the company earned $0.51 earnings per share. The business’s quarterly revenue was up 34.3% compared to the same quarter last year. Equities research analysts predict that Axon Enterprise, Inc. will post 2.35 EPS for the current year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Julie A. Cullivan sold 478 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total transaction of $136,727.12. Following the completion of the sale, the director now directly owns 5,546 shares in the company, valued at $1,586,377.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Axon Enterprise news, Director Julie A. Cullivan sold 478 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total transaction of $136,727.12. Following the completion of the sale, the director now directly owns 5,546 shares in the company, valued at $1,586,377.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Julie A. Cullivan sold 993 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the sale, the director now owns 4,553 shares of the company’s stock, valued at $1,282,671.16. The disclosure for this sale can be found here. Insiders sold 89,447 shares of company stock worth $27,684,677 over the last ninety days. Company insiders own 6.10% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.